【4576】デ・ウエスタン・セラピテクス研究所

創薬。眼病に注力。

類似企業：

【業界1位】小野薬品工業

【売上同水準】ヘリオス メドレックス

東証グロース

医薬品医薬

＞

その他医療・医薬品医他

売上高

営業利益

経常利益

当期利益

業績予想修正

対前回修正率

当初予想比較

決算期	日付	予・実	売上高 (百万円)	対前回	修正率	修正率	営業利益 (百万円)	対前回	修正率	修正率	経常利益 (百万円)	対前回	修正率	修正率	当期利益 (百万円)	対前回	修正率	修正率
2025.12	2025/02/10	当初予	400	-	-	-	-670	-	-	-	-680	-	-	-	-680	-	-	-
2024.12	2025/02/10	実	471	→	0.0%	+17.8%	-1,209	→	0.0%	+19.4%	-1,228	↑	+0.1%	+18.7%	-1,290	→	0.0%	+14.6%
2024.12	2025/01/16	修正予	471	↑	+17.8%	+17.8%	-1,209	↑	+19.4%	+19.4%	-1,229	↑	+18.6%	+18.6%	-1,290	↑	+14.6%	+14.6%
2024.12	2024/11/14	Q3予	400	→	0.0%	0.0%	-1,500	→	0.0%	0.0%	-1,510	→	0.0%	0.0%	-1,510	→	0.0%	0.0%
2024.12	2024/08/09	Q2予	400	→	0.0%	0.0%	-1,500	→	0.0%	0.0%	-1,510	→	0.0%	0.0%	-1,510	→	0.0%	0.0%
2024.12	2024/05/13	Q1予	400	→	0.0%	0.0%	-1,500	→	0.0%	0.0%	-1,510	→	0.0%	0.0%	-1,510	→	0.0%	0.0%
2024.12	2024/02/09	当初予	400	-	-	-	-1,500	-	-	-	-1,510	-	-	-	-1,510	-	-	-
2023.12	2024/02/09	実	428	↑	+4.4%	+7.0%	-798	↑	+6.1%	+43.0%	-796	↑	+6.4%	+43.5%	-812	↑	+6.7%	+41.6%
2023.12	2023/12/14	修正予	410	↑	+2.5%	+2.5%	-850	↑	+39.3%	+39.3%	-850	↑	+39.7%	+39.7%	-870	↑	+37.4%	+37.4%
2023.12	2023/11/10	Q3予	400	→	0.0%	0.0%	-1,400	→	0.0%	0.0%	-1,410	→	0.0%	0.0%	-1,390	→	0.0%	0.0%
2023.12	2023/08/10	Q2予	400	→	0.0%	0.0%	-1,400	→	0.0%	0.0%	-1,410	→	0.0%	0.0%	-1,390	→	0.0%	0.0%
2023.12	2023/05/12	Q1予	400	→	0.0%	0.0%	-1,400	→	0.0%	0.0%	-1,410	→	0.0%	0.0%	-1,390	→	0.0%	0.0%
2023.12	2023/02/13	当初予	400	-	-	-	-1,400	-	-	-	-1,410	-	-	-	-1,390	-	-	-
2022.12	2023/02/13	実	448	↑	+1.8%	+21.1%	-305	↑	+23.8%	+55.8%	-295	↑	+24.4%	+57.9%	-429	↓	-12.9%	+36.0%
2022.12	2022/11/18	修正予	440	↑	+18.9%	+18.9%	-400	↑	+42.0%	+42.0%	-390	↑	+44.3%	+44.3%	-380	↑	+43.3%	+43.3%
2022.12	2022/11/10	Q3予	370	→	0.0%	0.0%	-690	→	0.0%	0.0%	-700	→	0.0%	0.0%	-670	→	0.0%	0.0%
2022.12	2022/08/09	Q2予	370	→	0.0%	0.0%	-690	→	0.0%	0.0%	-700	→	0.0%	0.0%	-670	→	0.0%	0.0%
2022.12	2022/05/12	Q1予	370	→	0.0%	0.0%	-690	→	0.0%	0.0%	-700	→	0.0%	0.0%	-670	→	0.0%	0.0%
2022.12	2022/02/10	当初予	370	-	-	-	-690	-	-	-	-700	-	-	-	-670	-	-	-
2021.12	2022/02/10	実	414	↑	+3.5%	+21.8%	-171	↑	+10.0%	+70.5%	-159	↑	+16.3%	+72.6%	-148	↑	+12.9%	+72.1%
2021.12	2021/11/19	修正予	400	→	0.0%	+17.6%	-190	↑	+34.5%	+67.2%	-190	↑	+34.5%	+67.2%	-170	↑	+37.0%	+67.9%
2021.12	2021/11/11	Q3予	400	→	0.0%	+17.6%	-290	→	0.0%	+50.0%	-290	→	0.0%	+50.0%	-270	→	0.0%	+49.1%
2021.12	2021/10/11	修正予	400	↑	+17.6%	+17.6%	-290	↑	+50.0%	+50.0%	-290	↑	+50.0%	+50.0%	-270	↑	+49.1%	+49.1%
2021.12	2021/08/10	Q2予	340	→	0.0%	0.0%	-580	→	0.0%	0.0%	-580	→	0.0%	0.0%	-530	→	0.0%	0.0%
2021.12	2021/05/13	Q1予	340	→	0.0%	0.0%	-580	→	0.0%	0.0%	-580	→	0.0%	0.0%	-530	→	0.0%	0.0%
2021.12	2021/02/12	当初予	340	-	-	-	-580	-	-	-	-580	-	-	-	-530	-	-	-
2020.12	2021/02/12	実	355	→	0.0%	+14.5%	-265	→	0.0%	+8.6%	-289	→	0.0%	+6.8%	-276	→	0.0%	-15.0%
2020.12	2021/01/14	修正予	355	↑	+14.5%	+14.5%	-265	↑	+32.1%	+8.6%	-289	↑	+29.5%	+6.8%	-276	↑	+18.8%	-15.0%
2020.12	2020/11/12	Q3予	310	→	0.0%	0.0%	-390	→	0.0%	-34.5%	-410	→	0.0%	-32.3%	-340	→	0.0%	-41.7%
2020.12	2020/08/13	Q2予	310	→	0.0%	0.0%	-390	→	0.0%	-34.5%	-410	→	0.0%	-32.3%	-340	→	0.0%	-41.7%
2020.12	2020/05/14	Q1予	310	→	0.0%	0.0%	-390	→	0.0%	-34.5%	-410	→	0.0%	-32.3%	-340	→	0.0%	-41.7%
2020.12	2020/04/16	修正予	310	→	0.0%	0.0%	-390	↓	-34.5%	-34.5%	-410	↓	-32.3%	-32.3%	-340	↓	-41.7%	-41.7%
2020.12	2020/02/13	当初予	310	-	-	-	-290	-	-	-	-310	-	-	-	-240	-	-	-
2019.12	2020/02/13	実	580	→	0.0%	+16.0%	117	↑	+6.4%	+290.0%	109	↑	+9.0%	+445.0%	133	↑	+2.3%	+121.7%
2019.12	2019/12/12	修正予	580	↑	+16.0%	+16.0%	110	↑	+266.7%	+266.7%	100	↑	+400.0%	+400.0%	130	↑	+116.7%	+116.7%
2019.12	2019/11/14	Q3予	500	→	0.0%	0.0%	30	→	0.0%	0.0%	20	→	0.0%	0.0%	60	→	0.0%	0.0%
2019.12	2019/08/08	Q2予	500	→	0.0%	0.0%	30	→	0.0%	0.0%	20	→	0.0%	0.0%	60	→	0.0%	0.0%
2019.12	2019/05/15	Q1予	500	→	0.0%	0.0%	30	→	0.0%	0.0%	20	→	0.0%	0.0%	60	→	0.0%	0.0%
2019.12	2019/02/14	当初予	500	-	-	-	30	-	-	-	20	-	-	-	60	-	-	-
2018.12	2019/02/14	実	292	↑	+4.3%	-54.0%	-786	↓	-2.7%	-27.8%	-796	↓	-2.7%	-27.4%	-748	↓	-2.5%	-37.2%
2018.12	2018/12/27	修正予	280	↓	-26.3%	-55.9%	-765	↑	+6.1%	-24.4%	-775	↑	+6.1%	-24.0%	-730	↑	+2.0%	-33.9%
2018.12	2018/11/08	Q3予	380	→	0.0%	-40.2%	-815	→	0.0%	-32.5%	-825	→	0.0%	-32.0%	-745	→	0.0%	-36.7%
2018.12	2018/08/09	Q2予	380	→	0.0%	-40.2%	-815	→	0.0%	-32.5%	-825	→	0.0%	-32.0%	-745	→	0.0%	-36.7%
2018.12	2018/07/26	修正予	380	↓	-40.2%	-40.2%	-815	↓	-32.5%	-32.5%	-825	↓	-32.0%	-32.0%	-745	↓	-36.7%	-36.7%
2018.12	2018/05/10	Q1予	635	→	0.0%	0.0%	-615	→	0.0%	0.0%	-625	→	0.0%	0.0%	-545	→	0.0%	0.0%
2018.12	2018/02/13	当初予	635	-	-	-	-615	-	-	-	-625	-	-	-	-545	-	-	-
2017.12	2018/02/13	実	254	↑	+1.6%	-12.4%	-633	↓	-0.5%	+58.5%	-668	↑	+0.3%	+56.3%	-1,563	↓	-0.2%	-8.2%
2017.12	2017/12/27	修正予	250	↓	-34.2%	-13.8%	-630	↑	+7.4%	+58.7%	-670	↑	+6.9%	+56.2%	-1,560	↑	+6.6%	-8.0%
2017.12	2017/11/09	Q3予	380	→	0.0%	+31.0%	-680	→	0.0%	+55.4%	-720	→	0.0%	+52.9%	-1,670	→	0.0%	-15.6%
2017.12	2017/08/10	Q2予	380	→	0.0%	+31.0%	-680	→	0.0%	+55.4%	-720	→	0.0%	+52.9%	-1,670	→	0.0%	-15.6%
2017.12	2017/07/13	修正予	380	↑	+31.0%	+31.0%	-680	↑	+55.4%	+55.4%	-720	↑	+52.9%	+52.9%	-1,670	↓	-15.6%	-15.6%
2017.12	2017/05/15	Q1予	290	→	0.0%	0.0%	-1,525	→	0.0%	0.0%	-1,530	→	0.0%	0.0%	-1,445	→	0.0%	0.0%
2017.12	2017/02/23	当初予	290	-	-	-	-1,525	-	-	-	-1,530	-	-	-	-1,445	-	-	-
2016.12	2017/02/14	実	168	↑	+5.0%	+5.0%	-319	↑	+19.4%	+19.4%	-304	↑	+23.0%	+23.0%	-253	↑	+17.3%	+17.3%
2016.12	2016/08/10	Q2予	160	→	0.0%	0.0%	-396	→	0.0%	0.0%	-395	→	0.0%	0.0%	-306	→	0.0%	0.0%
2016.12	2016/02/12	当初予	160	-	-	-	-396	-	-	-	-395	-	-	-	-306	-	-	-
2015.12	2016/02/12	実	61	→	0.0%	-	-290	→	0.0%	0.0%	-295	→	0.0%	-	-296	→	0.0%	-
2015.12	2016/02/10	修正予	61	↑	-	-	-290	-	-	-	-295	↓	-	-	-296	↓	-	-
2015.12	2015/02/12	当初予	0	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-
2014.12	2015/02/12	実	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2014.12	2014/12/02	修正予	80	↑	+100.0%	+100.0%	-203	↑	+16.5%	+16.5%	-200	↑	+16.7%	+16.7%	-201	↑	+16.6%	+16.6%
2014.12	2014/11/13	Q3予	40	→	0.0%	0.0%	-243	→	0.0%	0.0%	-240	→	0.0%	0.0%	-241	→	0.0%	0.0%
2014.12	2014/08/12	Q2予	40	→	0.0%	0.0%	-243	→	0.0%	0.0%	-240	→	0.0%	0.0%	-241	→	0.0%	0.0%
2014.12	2014/05/14	Q1予	40	→	0.0%	0.0%	-243	→	0.0%	0.0%	-240	→	0.0%	0.0%	-241	→	0.0%	0.0%
2014.12	2014/02/13	当初予	40	-	-	-	-243	-	-	-	-240	-	-	-	-241	-	-	-
2013.12	2014/02/13	実	80	-	-	-	-208	-	-	-	-221	-	-	-	-222	-	-	-

【4576】デ・ウエスタン・セラピテクス研究所 創薬。眼病に注力。 類似企業： 【業界1位】 小野薬品工業 【売上同水準】 ヘリオス メドレックス

【4576】デ・ウエスタン・セラピテクス研究所

創薬。眼病に注力。

類似企業：

【業界1位】小野薬品工業

【売上同水準】ヘリオスメドレックス